Mannkind

Summer Street put out a note discussing MannKind's (Nasdaq: MNKD) Afrezza. Overall, analysts are much more optimistic current trials could allow FDA approval, which is likely assuming endpoints are meet and there are no safety concerns. Analyst said a former FDA reviewer sees an 85% chance Afrezza's type 1 diabetes study will meet endpoints of non-inferiority to injectable insulin, and equivalence to insulin using the old inhaler.

http://www.streetinsider.com/Analyst+Comments/Summer+Street+Optimistic+Regarding+FDA+Approval+of+MannKinds+%28MNKD%29+Afrezza/8438590.html